Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614024 · ClinicalTrials.gov registry record · NA
Neurofeedback During Eating for Bulimia Nervosa
A NA study of Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05614024: Recruiting NA study of Bulimia Nervosa, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05614024 is a NA study of Bulimia Nervosa that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 1,737-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614024, a NA study of Bulimia Nervosa, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.
Primary Outcome
The investigators will evaluate changes in PFC neural activation and connectivity as a function of neurofeedback.
Conditions Studied
Interventions
- OTHER Real fNIRS Neurofeedback
- OTHER Sham-Control fNIRS Neurofeedback
Study Locations (1)
New York
- Center for Computational Psychiatry at the Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT05614024 shows while recruiting
NCT05614024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,737-participant average among 23 other Bulimia Nervosa trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Bulimia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Real fNIRS Neurofeedback is the first listed.
NCT05614024 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05614024 about?
NCT05614024 is a clinical study titled "Neurofeedback During Eating for Bulimia Nervosa". The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influen...
What is the current status of trial NCT05614024?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-05-13. Estimated completion is 2027-12.
What conditions does trial NCT05614024 study?
This clinical trial studies the following conditions: Bulimia Nervosa.
What interventions are being tested in trial NCT05614024?
The interventions under investigation include: Real fNIRS Neurofeedback (OTHER), Sham-Control fNIRS Neurofeedback (OTHER).
Who is sponsoring clinical trial NCT05614024?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05614024 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bulimia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05614024's enrollment target sits among peer trials
30 17th of 23 higher than 6 of 23 other Bulimia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bulimia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Changes in Inhibition and Valuation After Eating
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
-
Building an Equitable and Accessible System of Eating Disorder Care for VA, DoD, and Underrepresented Americans
RECRUITING · NA
-
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI